Mucopolysaccaridosis II: new pathogenic mutation in IDS gene)

Authors

  • Eugenia Pérez Elizondo Caja Costarricense del Seguro Social, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera"
  • Alejandra Acosta Gualandri Caja Costarricense del Seguro Social, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera"
  • Mildred Jiménez Hernández Caja Costarricense del Seguro Social, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera"

DOI:

https://doi.org/10.51481/amc.v56i4.859

Keywords:

mucopolysaccaridosis, Hunter Syndrome, lysosomal disease, iduronate-2-sulphatase enzyme, glycosaminoglycans

Abstract

Mucopolysaccharidosis type II is a lisosomal disorder caused by a deficiency of the iduronate 2 sulphatase enzyme. It is a rare metabolic disease with an X linked recessive inheritance that may cause important progressive disability. Molecular analysis is a useful technique to confirm diagnosis and to identify asymptomatic carriers, thus allowing genetic counseling. We report the case of a patient with Muchopolysacharidosis type II with a new pathogenic mutation in the IDS gene.

Downloads

Download data is not yet available.

References

Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008;167:3:267-77.

Guelbert N, Amartino H, Arberas C, Azar N, Bay L, Fainboim A, et al. GUideline for diagnosis, follow-up and treatment of mucopolysaccharidoses type II or Hunter disease. Arch Argent Pediatr. 2011;109:2:175-81.

Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005,32:270-2.

Rigante D, Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology.2002;98:18-20.

Leighton SE, Papsin B, Vellodi A, Dinwiddie R, Lane R. Disordered breathing during sleep in patients with mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2001;58:127-38.

Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2005; 69:589-95.

Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Muñoz V et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter Syndrome). Pediatr. 2008;121:377.

Apéstegui A, Trejos R, Blanco A, González L. Valores normales de mucopolisacáridos en orina de niños. Rev. Med. Hosp. Nal. Niños Costa Rica.

;215-224.

Stenson PD, Mort M, Ball EV, Shaw K, Phillips AD, Cooper DN. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet. 2013. En: www.hgmd.cf.ac.uk.

Malatack JJ, Consolini DM, Bayever E. The status of hematopoietic stem cell transplantation in lysosomal storage disease. Pediatr Neurol. 2003; 29:391-403.

Published

2014-10-01

Versions

How to Cite

Mucopolysaccaridosis II: new pathogenic mutation in IDS gene). (2014). Acta Médica Costarricense , 56(4), 180-182. https://doi.org/10.51481/amc.v56i4.859 (Original work published 2015)